Amsilk partners with 21st.BIO
AMSilk GmbH and Danish 21st.BIO A/S announce partnership to accelerate the production of advanced materials made from spider silk-based proteins.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1164 entries already.
Entries by Thomas Gabrielczyk
Onera Health raises US$32m in Series C round
/in News/by Thomas GabrielczykSleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv.
Spexis sells antibiotics programme to Basilea
/in News/by Thomas GabrielczykMacrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.
Finnish Enifer Oy secures €12m grant to scale up
/in News/by Thomas GabrielczykMicrobial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually.
Mogu Srl raises €11m to scale mycelium technology
/in News/by Thomas GabrielczykItalian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the European Circular Bioeconomy Fund (ECBF VC)
Novo Nordisk Foundation in US$25m partnership with CARB-X
/in News/by Thomas GabrielczykNovo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.<br /><br />
Novartis AG to buy immunology specialist Calypso Biotech BV
/in News/by Thomas Gabrielczyk<a title="http://www.b3cnewswire.com/PRT/link.php?click=1630-2-24167-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000" target="_blank" rel="nofollow noopener" href="http://www.b3cnewswire.com/PRT/link.php?click=1630-2-24167-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000">Calypso Biotech BV</a> has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up […]
GLP1 agonists: FDA investigates suicide risk
/in News/by Thomas GabrielczykFollowing in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.<br /><br /><br />
Boehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.
/in News/by Thomas GabrielczykBoehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd. <br /><br />
miRNA specialist Resalis Therapeutics Srl raises €10m in Series A financing
/in News/by Thomas GabrielczykItalian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.